about
Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphomaDownregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.Leukemia cell to endothelial cell communication via exosomal miRNAs.Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of ImatinibTeriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells.Reduced fertility with impairment of early-stage embryos observed in mice lacking Lgr4 in epithelial tissues.Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing.Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant CellsExosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell TransplantationLineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasmNon-random chromosomal deletion clustering at 20q in Waldenström macroglobulinemiaReconstruction of oviduct and demonstration of epithelial fate determination in miceThe BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib]Stratification of mouse vaginal epithelium 2. Identification of factors inducing stratificationStratification of mouse vaginal epithelium. 1. Development of three-dimensional models in vitro with clonal cell linesHidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemiaExtracellular vesicle-mediated cell-cell communication in haematological neoplasmsReplenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesisDownregulation of extracellular vesicle microRNA-101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progressionInduction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretionMaintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangementPredisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphomaEffect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesisAuthor Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasmA novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndromeBIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma
P50
Q33839512-3A71DCAA-5435-4391-B708-956DEA78FE24Q34109784-FAAB5E4F-866D-4FF8-9423-B8AC718200F6Q39314508-0C3D0771-7768-4619-9A31-28AF23F1FB96Q40752763-C38DFFBE-8EC4-4C4F-83ED-34EA69F1CA62Q42378391-B880515A-0CA0-4D69-90D0-9F7646CB4B63Q51552375-510B1552-26DD-4E35-8CD4-42FDD4AC8EA3Q51780273-A132B94F-934C-4074-A070-C732AC9C59A9Q58554160-39BFBF92-827A-4CDF-BEDF-75B283829584Q58710237-B55FED20-94A9-4F84-9A6A-D2645B21CA4BQ64060619-50E6E232-96C8-4075-8ECA-A4BD5D02979EQ84349974-D4D94EB7-14CD-40CC-901A-AC543C626112Q84886723-E30172B5-1012-49F7-B6C7-3214FBA3B1A0Q85330830-225CC60D-1472-4301-B652-53E9CC3F8233Q86916349-6BCD3249-C143-47AE-9D28-E3301331E3FFQ88677789-3EF29A84-2102-4B3B-9BF7-48F2E3E591D0Q88691933-2EDE025B-4D90-42B3-8349-B88289EB9F36Q89131873-787399A6-7C12-404E-956D-23DB04F29C81Q89344641-D906C428-092A-472F-9E7A-13A4B6161BB2Q89776917-352EE3D1-8443-4594-8B36-B74E40C62D7EQ90480708-2ABBA7DB-AD72-438F-956E-69E24326DCCEQ91167243-C1168E84-08BD-4DAA-BC08-17177CA85383Q91168777-9DDF137C-0A9B-4013-B5F3-6C6B8A8CC699Q91172450-50D7F945-4052-411C-9E0D-9630EDF70417Q91846787-815ADDEE-AF14-4807-9718-8B223CEFA483Q92965454-04451731-F266-4AD9-9DA5-87906B3AD197Q93025816-410D7915-81ED-46C4-9F68-9EE2D94016F4Q93334395-15FA16E1-037A-4775-BF3A-10C19629F197
P50
description
researcher ORCID ID = 0000-0002-0123-8921
@en
wetenschapper
@nl
name
Tomohiro Umezu
@ast
Tomohiro Umezu
@en
Tomohiro Umezu
@es
Tomohiro Umezu
@nl
type
label
Tomohiro Umezu
@ast
Tomohiro Umezu
@en
Tomohiro Umezu
@es
Tomohiro Umezu
@nl
prefLabel
Tomohiro Umezu
@ast
Tomohiro Umezu
@en
Tomohiro Umezu
@es
Tomohiro Umezu
@nl
P106
P1153
36834587600
P31
P496
0000-0002-0123-8921